Home / Resource Library / Preliminary Safety and Efficacy from a Multicenter, Investigator Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)
Preliminary Safety and Efficacy from a Multicenter, Investigator Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)